Jardiance Improves Double-Digit Growth Potential With US Approval In CKD
Slight Advantage Over Farxiga In Same Indication
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.
You may also be interested in...
Highly anticipated list will determine the Medicare Part D drugs subject to negotiated prices in 2026. Under the law, the list cannot be subject to administrative or judicial review, so the stakes are high. As patent and sales statuses shift, Scrip offers a baker's dozen of possible drugs.
The SGLT2 inhibitor has won European approval for the treatment of chronic kidney disease and while rival AstraZeneca’s Farxiga has had a two-year head start in the space, Boehringer and Lilly could come out on top given Jardiance’s stronger sales records to date.
Industry leaders are concerned about the outlook for small molecule drugs in particular, but execs at the J.P. Morgan Healthcare Conference were also optimistic there could be chances to shape the implementation of certain policies.